Pneumococcal Disease News and Research

RSS

Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise.

11 Feb 2014

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Children hospitalized for pneumonia have similar outcomes, including length of stay and costs, regardless of whether they are treated with "big gun" antibiotics such as ceftriaxone or cefotaxime or more narrowly focused antibiotics such as ampicillin or penicillin, according to a Vanderbilt study published in Pediatrics.

10 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

New NPS Direct article reveals that vaccinations fight against antibiotic resistance

During Antibiotic Awareness Week (18-24 November) NPS MedicineWise is urging health professionals to use vaccinations as one important way to limit Australia’s use of antibiotics.

22 Nov 2013

New NPS Direct article reveals that vaccinations fight against antibiotic resistance

During Antibiotic Awareness Week (18-24 November) NPS MedicineWise is urging health professionals to use vaccinations as one important way to limit Australia’s use of antibiotics.

22 Nov 2013

Griffith University launches new online scholarly journal to fight against pneumonia

Advancing the fight against pneumonia is the focus of a new online scholarly journal launched by Griffith University ePress.

11 Nov 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Urinary pneumococcal antigen testing ‘useful in children’

Urinary antigen testing is effective in detecting invasive pneumococcal pneumonia in children, say the authors of a UK-based case–control study.

23 Sep 2013

Inhaled corticosteroids increase pneumonia risk in asthma

Research from the UK indicates that the use of inhaled corticosteroids is independently associated with an increased risk for pneumonia and lower respiratory tract infection in patients with asthma.

12 Sep 2013

Study finds similar antibody levels among 4 PCV13 immunization schedules

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

5 Sep 2013

Immunization in developing countries: an interview with Dr. Jos Vandelaer, Chief of Immunization for UNICEF

Overall, worldwide, immunization programs reach around 83% of all children – this is an enormous achievement. With this level of immunization coverage, we prevent over 2 million deaths, year after year. This statistic is often forgotten or taken for granted.

11 Jul 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria.

12 Mar 2013

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).

5 Mar 2013

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

One of the key reasons why children are missed by immunization programs, particularly in developing countries where Médecins Sans Frontières (MSF) works, is that the products that we currently have in their present formulation are not well-suited to the places that have the most un-immunized children. These are the most challenging contexts to work in.

19 Feb 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013

High vaccine prices ignored by ‘Decade of Vaccines’ blueprint

Governments meeting at the World Health Organization’s Executive Board (WHO EB) this week must seize the opportunity to improve serious shortcomings in the document that will drive the global community’s vaccines response in the next few years. If they fail to do so, key reasons why children continue to be missed by immunisation programmes will be left unaddressed.

25 Jan 2013

Madagascar faces challenges in vaccinating children

"In Madagascar, pneumonia is responsible for 21 percent of deaths among children under five years old -- making it the leading cause of death for this age group," but "[t]he recent introduction of a vaccine to protect against pneumococcal disease, the leading cause of severe childhood pneumonia, is attempting to reduce the thousands of child deaths that occur every year in" the country, IRIN reports.

24 Jan 2013

Pneumococcal Disease News and Research

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

New NPS Direct article reveals that vaccinations fight against antibiotic resistance

New NPS Direct article reveals that vaccinations fight against antibiotic resistance

Griffith University launches new online scholarly journal to fight against pneumonia

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Urinary pneumococcal antigen testing ‘useful in children’

Inhaled corticosteroids increase pneumonia risk in asthma

Study finds similar antibody levels among 4 PCV13 immunization schedules

Immunization in developing countries: an interview with Dr. Jos Vandelaer, Chief of Immunization for UNICEF

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

High vaccine prices ignored by ‘Decade of Vaccines’ blueprint

Madagascar faces challenges in vaccinating children

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News